PATENT CLAIM ANALYSIS

Application Number: 16118760
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["546", "119000"]

Abstract:
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Claim (Index 48):
The method of  claim 47 , wherein the HBV vaccine is selected from the group consisting of RECOMBIVAX HB, ENGERIX-B, ELOVAC B, GENEVAC-B, and SHANVAC B.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 96.0
- Lexical Diversity: 1.42308
- Patent Class: 546.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14984325', '15843598', '14984293', '15347468', '14984654']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8888726861280924
- 35 USC 102 Novelty (BERT): 0.6550066120695919
- Combined Prediction Score: 0.8654860787222424
- Mean Citation Score: 697.37725
- Max Citation Score: 724.7858
- Similarity Product: 613.3198707036734

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test